Bioequivalence of Betis®10 mg Film-Coated Tablets versus Clozan 10 mg tablets in Healthy Subjects

2023-504901-34-00 Protocol BLCL-CLT-01 Human pharmacology (Phase I) - Bioequivalence study Ended

Start 15 Jul 2024 · End 2 Dec 2024 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol BLCL-CLT-01

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Bioequivalence study
Status Ended
Participants planned 44
Countries 1
Sites 1

No medical condition.

Key facts

Sponsor
Synthon Chile LTDA.
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Not possible to specify
Trial duration
15 Jul 2024 → 2 Dec 2024
Decision date (initial)
2024-05-14
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

No medical condition.

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Synthon Chile LTDA.

Sponsor organisation
Synthon Chile LTDA.
Address
El Castano 145, Valle Grande, Lampa Valle Grande Lampa
City
Santiago
Postcode
9380000
Country
Chile

Scientific contact point

Organisation
Synthon Chile LTDA.
Contact name
Synthon BV, Department of Clinical Research and Development

Public contact point

Organisation
Synthon Chile LTDA.
Contact name
Synthon BV, Department of Clinical Research and Development

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Portugal Ended 44 1
Rest of world 0

Investigational sites

Portugal

1 site · Ended
Blueclinical Investigacao E Desenvolvimento Em Saude Lda.
Medical Management, Hospital Da Prelada 0 Floor And 3 rd Floor, Rua Sarmento De Beires 153, Porto

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Portugal 2024-07-15 2024-12-02 2024-07-15 2024-11-21

Application history

3 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-04-05 Portugal Acceptable
2024-05-10
2024-05-14
2 SUBSTANTIAL MODIFICATION SM-1 2024-10-22 Portugal Acceptable
2024-11-12
2024-11-14
3 SUBSTANTIAL MODIFICATION SM-2 2024-12-19 Portugal Acceptable 2025-01-22